$29.10−0.07 (−0.24%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Amphastar Pharmaceuticals (AMPH) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue fell 1.7% in FY25, net margin 13.6%, and free cash flow (~$121.2M) tracks net income. Earnings are cash, not paper.
The four lines that matter · FY21–FY25
Revenue ($M)▼1.7%
719.9
FY21→FY25CAGR +13.2%/yr
Net income ($M)▼38.5%
98.1
FY21→FY25CAGR +11.6%/yr
Free cash flow ($M)▼29.7%
121.2
FY21→FY25CAGR +14.5%/yr
Diluted EPS▼33.7%
2.03
buyback-liftedCAGR +12.9%/yr
What the receipts whisper · what a headline number hides
Share count
−3.2%
49.8mn → 48.2mn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.
Capex
$34.9M
−15.0% YoY in FY25 · 4.8% of revenue.
Returns vs FCF
62%
$75.6M returned vs $121.2M of FCF in FY25. Buybacks covered by cash flow.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
14¢ of every revenue dollar becomes profit. The biggest cost lever is COGS.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 45.6% → 49.5%. Net margin 13.6% is more than double the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 745.8 | 719.9 | 732.0 | 644.4 | 499.0 | 437.8 | ▼1.7% | +13.2% |
Cost of revenue | 396.7 | 363.8 | 358.1 | 293.3 | 250.1 | 238.0 | ▲1.6% | +11.2% |
Gross profit | 349.1 | 356.1 | 373.9 | 351.1 | 248.9 | 199.7 | ▼4.8% | +15.5% |
Research & development | 92.3 | 85.8 | 73.9 | 73.7 | 74.8 | 60.9 | ▲16.1% | +8.9% |
Selling, general & admin | 69.6 | 85.9 | 56.7 | 51.5 | 45.1 | 51.4 | ▲51.5% | +13.7% |
Total operating expenses | 209.4 | 215.7 | 168.4 | 154.1 | 141.4 | 129.9 | ▲28.0% | +13.5% |
Operating incomefeeds ROC rank | 139.7 | 140.4 | 205.4 | 197.0 | 107.5 | 69.9 | ▼31.7% | +19.1% |
Other income, net | −10.2 | −16.8 | −15.7 | −25.6 | 8.5 | 14.3 | — | — |
Pretax income | 129.6 | 123.6 | 189.8 | 171.4 | 116.0 | 84.1 | ▼34.9% | +10.1% |
Income tax | 30.6 | 25.5 | 29.7 | 31.8 | 23.5 | 20.6 | ▼14.0% | +5.5% |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 99.0 | 98.1 | 159.5 | 137.5 | 91.4 | 63.3 | ▼38.5% | +11.6% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 2.19 | 2.03 | 3.06 | 2.60 | 1.74 | 1.25 | ▼33.7% | +12.9% |
Diluted shares (mn) | 43.38 | 48.22 | 52.06 | 53.00 | 52.43 | 49.78 | ▼7.4% | −0.8% |
| Margins | ||||||||
Gross margin26th pct in Healthcare | 46.8% | 49.5% | 51.1% | 54.5% | 49.9% | 45.6% | ▼1.6pp | +3.8pp |
Operating margin | 18.7% | 19.5% | 28.1% | 30.6% | 21.5% | 16.0% | ▼8.6pp | +3.5pp |
Net margin74th pct in Healthcare | 13.3% | 13.6% | 21.8% | 21.3% | 18.3% | 14.5% | ▼8.2pp | −0.8pp |
† TTM = trailing four quarters through 2026-09-30.
5 more years of statements and CSV export are on Premium, and 9 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Amphastar Pharmaceuticals' revenue last fiscal year?
Amphastar Pharmaceuticals reported revenue of $719.9M in fiscal 2025, down 1.7% from fiscal 2024.
What was Amphastar Pharmaceuticals' net income?
Amphastar Pharmaceuticals reported net income of $98.1M in fiscal 2025, a net margin of 13.6%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

